These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29466885)

  • 1. Intralesional therapy as a treatment for locoregionally metastatic melanoma.
    Miura JT; Zager JS
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):399-408. PubMed ID: 29466885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional immunotherapy as a strategy to treat melanoma.
    Nouri N; Garbe C
    Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional therapy for metastatic melanoma.
    Sloot S; Rashid OM; Zager JS
    Expert Opin Pharmacother; 2014 Dec; 15(18):2629-39. PubMed ID: 25381015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional therapies for locoregionally advanced and unresectable melanoma.
    Weitman ES; Zager JS
    Clin Exp Metastasis; 2018 Aug; 35(5-6):495-502. PubMed ID: 29736626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Locoregionally Advanced Melanoma.
    Pointer DT; Zager JS
    Surg Clin North Am; 2020 Feb; 100(1):109-125. PubMed ID: 31753106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional therapy for in-transit and satellite metastases in melanoma.
    Feeney KJ; Mastrangelo MJ
    Surg Oncol Clin N Am; 2015 Apr; 24(2):299-308. PubMed ID: 25769713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional PV-10 for in-transit melanoma-A single-center experience.
    Lippey J; Bousounis R; Behrenbruch C; McKay B; Spillane J; Henderson MA; Speakman D; Gyorki DE
    J Surg Oncol; 2016 Sep; 114(3):380-4. PubMed ID: 27237868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
    Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
    Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoablation of metastatic melanoma using intralesional Rose Bengal.
    Thompson JF; Hersey P; Wachter E
    Melanoma Res; 2008 Dec; 18(6):405-11. PubMed ID: 18830132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
    Thompson JF; Agarwala SS; Smithers BM; Ross MI; Scoggins CR; Coventry BJ; Neuhaus SJ; Minor DR; Singer JM; Wachter EA
    Ann Surg Oncol; 2015 Jul; 22(7):2135-42. PubMed ID: 25348780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?
    Testori A; Intelisano A; Verrecchia F; Menicanti C; Tosti G; Grassi E; Pari C; Pennacchioli E
    Dermatol Ther; 2012; 25(5):443-51. PubMed ID: 23046023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma.
    Ross MI
    J Surg Oncol; 2014 Mar; 109(4):314-9. PubMed ID: 24510477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in Intralesional Therapy for Metastatic Melanoma.
    Sloot S; Rashid OM; Sarnaik AA; Zager JS
    Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.
    Rashid OM; Sloot S; Zager JS
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1355-64. PubMed ID: 25176398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.